These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20572339)

  • 1. [Construction, expression and immunogenicity analysis of a fusion protein containing M2e of influenza A virus fused to a modified Pseudomonas aeruginosa exotoxin A].
    Xu Y; Yao LH; Chen AJ; Guo JQ; Liu XY; Bo H; Liu LQ; Shu YL; Zhang ZQ
    Bing Du Xue Bao; 2010 May; 26(3):189-94. PubMed ID: 20572339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus.
    Challa S; Barrette R; Rood D; Zinckgraf J; French R; Silbart L
    Vaccine; 2007 Apr; 25(17):3328-37. PubMed ID: 17276557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
    Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
    PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.
    Wang W; Huang B; Jiang T; Wang X; Qi X; Gao Y; Tan W; Ruan L
    PLoS One; 2012; 7(12):e52488. PubMed ID: 23285063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
    Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
    Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonossoff GP; Ravin NV
    Bioengineered; 2016; 7(1):28-32. PubMed ID: 26710263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
    Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
    Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.
    Zhao G; Miao Y; Guo Y; Qiu H; Sun S; Kou Z; Yu H; Li J; Chen Y; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2014; 10(12):3649-58. PubMed ID: 25483702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
    Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.
    Deng L; Ibañez LI; Van den Bossche V; Roose K; Youssef SA; de Bruin A; Fiers W; Saelens X
    PLoS One; 2015; 10(5):e0126650. PubMed ID: 25973787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses.
    Mrsny RJ; Daugherty AL; Fryling CM; FitzGerald DJ
    Vaccine; 1999 Mar; 17(11-12):1425-33. PubMed ID: 10195778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes.
    Stepanova LA; Mardanova ES; Shuklina MA; Blokhina EA; Kotlyarov RY; Potapchuk MV; Kovaleva AA; Vidyaeva IG; Korotkov AV; Eletskaya EI; Ravin NV; Tsybalova LM
    J Biomed Sci; 2018 Apr; 25(1):33. PubMed ID: 29631629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
    Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
    Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.